Sat, Jun 13, 2026 | Updated 01:24 IST
Jan 02, 2026
Nadda highlighted that the Indian Pharmacopoeia serves as the official book of standards for drugs in the country and is a cornerstone of India's regulatory framework for pharmaceuticals. He stated that the 10th edition reflects scientific advancements, global best practices, and India's growing leadership in pharmaceutical manufacturing and regulation.
"Our refined copper balance for 2026 is now showing a deficit of around 600kt for 2026, following a deficit of around 200kt in 2025", the report stated.
More News
Credit growth in the country is expected to remain at around 12 per cent year-on-year in FY26 and...
The Indian automotive sector is preparing for a series of high-profile vehicle launches scheduled for early 2026, signalling...
ICICI Securities noted that EBITDA per tonne for spot steel has already risen by Rs 2,500-3,000, with a...